In vivo gene therapy delivery procedure and device

US12303687B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12303687-B2
Application numberUS-202217987578-A
CountryUS
Kind codeB2
Filing dateNov 15, 2022
Priority dateJul 24, 2018
Publication dateMay 20, 2025
Grant dateMay 20, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A “localizable” systemic gene therapy system is provided substantially increasing the transfection efficiency of the gene vectors into targeted tissue cells and substantially reducing the escape of the gene vectors from the targeted tissue volume, such as would waste the vectors, promote undesired immune reactions, and/or incur prohibitive costs for the required dose of gene-containing virus vectors. In this regard, the invention provides a means to simultaneously achieve local electroporation and gene-containing vector injection in a portion of a vascularized organ. It includes two double-balloon catheters that create contained volumes in parallel blood vessels for the introduction of vectors with reduced loss along with electrodes providing electroporation of the cells in the same location where the vectors are injected.

First claim

Opening claim text (preview).

What we claim is: 1. A gene delivery system for delivering viral vectors containing genetic material into cells of a patient, comprising: a first electrode insertable into a first blood vessel of the patient; a second electrode insertable into a second blood vessel of the patient; and an electric pulse generator configured to deliver at least one electric pulse to at least one of the first and second electrodes to apply a voltage between the first and second electrodes and create an electric field across the first and second electrodes and on cells surrounding the electrodes to increase the transduction rate of viral vectors into the cells of the patient; wherein each of the first and second electrodes comprises a coaxial conductor having an inner coaxial conductive element and an outer coaxial conductive element, and wherein the outer coaxial conductive element is absent from the coaxial conductor at a distal portion of the coaxial conductor to allow transmission of an electric field for electroporation. 2. The system of claim 1 further comprising a first catheter comprising a distal end defining a delivery portion and at least one passageway through a lumen of the catheter for the delivery of at least one viral vector wherein the first electrode extends along the first catheter; and a second catheter comprising a distal end defining a delivery portion and at least one passageway through a lumen of the catheter for the delivery of at least one viral vector wherein the second electrode extends along the second catheter. 3. The system of claim 1 wherein the at least one electrical pulse is configured to produce an electric field strength between the first and second electrode and a pulse duration that increases the delivery of viral vectors into cells surrounding the electrodes according to a processor executing a program held in stored memory. 4. The system of claim 3 wherein the at least one electrical pulse is configured to produce an electric field strength between the first and second electrode that is 100-200 V/cm. 5. The system of claim 4 wherein the at least one electrical pulse has a pulse duration of 38-100 msec. 6. The system of claim 3 wherein the at least one electrical pulse is configured to produce an electric field strength between the first and second electrode that is 200-275 V/cm. 7. The system of claim 6 wherein the at least one electrical pulse has a pulse duration of about 50 msec. 8. The system of claim 3 wherein the shape of the electric pulse and number of pulses of the electrical charge are configured to produce an electric field increasing the delivery of viral vectors into the cells surrounding the first and second electrodes according to a processor executing a program held in stored memory. 9. The system of claim 1 wherein the at least one viral vector contains foreign, functional genes. 10. A method for delivering one or more viral vectors containing genetic material into cells of a patient, comprising: inserting a first electrode into a first blood vessel of the patient, the first electrode comprising a first coaxial conductor having an inner coaxial conductive element and an outer coaxial conductive element, the outer coaxial conductive element being absent from the first coaxial conductor at a distal portion of the first coaxial conductor to allow transmission of an electric field for electroporation; inserting a second electrode into a second blood vessel of the patient the second electrode comprising a second coaxial conductor having an inner coaxial conductive element and an outer coaxial conductive element, the outer coaxial conductive element being absent from the second coaxial conductor at a distal portion of the second coaxial conductor to allow transmission of the electric field; injecting the at least one viral vector into the patient; and delivering at least one electrical pulse to at least one of the first and second electrodes configured to apply a voltage between electrodes and create the electric field across the first and second electrodes and on cells surrounding the electrodes to increase the transduction rate of viral vectors into the cells surrounding the electrodes of the patient. 11. The method of claim 10 further comprising providing a first catheter comprising a distal end to define a delivery portion, at least one passageway through a lumen of the catheter for the delivery of the at least one viral vector through the delivery portion, and a proximal end having a therapeutic injection port; inserting the first catheter into the first blood vessel of the patient; providing a second catheter comprising a distal end to define a delivery portion, at least one passageway through a lumen of the catheter for the delivery of at least one viral vector through the delivery portion, and a proximal end having a therapeutic injection port; and inserting the second catheter into the second blood vessel of the patient. 12. The method of claim 10 wherein the at least one electrical pulse is configured to produce an electric field strength between the first and second electrode and a pulse duration that increases the delivery of viral vectors into the cells surrounding the first and second electrodes according to a processor executing a program held in stored memory. 13. The method of claim 12 wherein the at least one electric pulse is configured to produce an electric field strength between the first and second electrode that is 100-200 V/cm. 14. The method of claim 13 wherein the at least one electrical pulse has a pulse duration of 38-100 msec. 15. The method of claim 12 wherein the at least one electric pulse is configured to produce an electric field strength between the first and second electrode that is 200-275 V/cm. 16. The system of claim 15 wherein the at least one electrical pulse has a pulse duration of about 50 msec. 17. The method of claim 10 wherein the at least one viral vector delivers foreign, functional genes into the cells of the patient. 18. The method of claim 10 wherein the first and second electrodes are inserted into first and second blood vessels located within a vascularized organ, tissue, or tumor. 19. The method of claim 18 wherein the first and second electrodes are inserted into first and second blood vessels located in a liver of the patient.

Assignees

Inventors

Classifications

  • Medical syringes, e.g. enemata; Irrigators (A61M5/00 takes precedence; pistons A61M5/315) · CPC title

  • characterised by an aspect of the administration regime · CPC title

  • for temporarily occluding a vessel for isolating a sector · CPC title

  • Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008}) · CPC title

  • Arrangements where at least part of the apparatus is introduced into the body · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12303687B2 cover?
A “localizable” systemic gene therapy system is provided substantially increasing the transfection efficiency of the gene vectors into targeted tissue cells and substantially reducing the escape of the gene vectors from the targeted tissue volume, such as would waste the vectors, promote undesired immune reactions, and/or incur prohibitive costs for the required dose of gene-containing virus ve…
Who is the assignee on this patent?
Wisconsin Alumni Res Found
What technology area does this patent fall under?
Primary CPC classification A61N1/325. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).